These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 11932714)
1. On the offensive. Abbott A Nature; 2002 Apr; 416(6880):470-4. PubMed ID: 11932714 [No Abstract] [Full Text] [Related]
2. [Molecular treatment of cancer. Imatinib]. Lopez M Clin Ter; 2001; 152(6):399-407. PubMed ID: 11865537 [No Abstract] [Full Text] [Related]
3. Progressive thoughts about progressive disease. Shah NP Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748 [No Abstract] [Full Text] [Related]
4. Imatinib: the promise of a "magic bullet" for cancer fulfilled. Henderson CA J Med Assoc Ga; 2003; 92(1):12-4, 22. PubMed ID: 12743899 [No Abstract] [Full Text] [Related]
5. [Pharmazie in unserer Zeit 5/2008]. Dingermann T; Laufer S; Winckler T Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281 [No Abstract] [Full Text] [Related]
7. Unexplored pharmacokinetic opportunities with microdosing in oncology. Sparreboom A Clin Cancer Res; 2007 Jul; 13(14):4033-4. PubMed ID: 17634525 [No Abstract] [Full Text] [Related]
8. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Rosti G; Martinelli G; Baccarani M Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121 [No Abstract] [Full Text] [Related]
9. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Atallah E; Kantarjian H; Cortes J Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119 [No Abstract] [Full Text] [Related]
10. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Hatfield A; Owen S; Pilot PR Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118 [No Abstract] [Full Text] [Related]
11. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117 [No Abstract] [Full Text] [Related]
12. Imatinib: the narrow line between immune tolerance and activation. Mohty M; Blaise D; Olive D; Gaugler B Trends Mol Med; 2005 Sep; 11(9):397-402. PubMed ID: 16087402 [TBL] [Abstract][Full Text] [Related]
13. New Gleevec treatment approved. FDA Consum; 2002; 36(2):6. PubMed ID: 11989477 [No Abstract] [Full Text] [Related]
14. Catastrophic tumour lysis syndrome following single dose of imatinib. Keane C; Henden A; Bird R Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739 [No Abstract] [Full Text] [Related]
15. Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. Altucci L; Balducci L; Irminger-Finger I Int J Biochem Cell Biol; 2007; 39(7-8):1278-9. PubMed ID: 17548227 [No Abstract] [Full Text] [Related]
16. Advances in molecular targets and cancer therapeutics. Westwell AD Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538 [No Abstract] [Full Text] [Related]
18. Effective treatment of a case of refractory mycosis fungoides with imatinib. Oka S; Yokote T; Hara S; Akioka T; Kobayashi K; Hirata Y; Yamano T; Endo Y; Tsuji M; Hanafusa T Br J Haematol; 2006 May; 133(4):353. PubMed ID: 16643439 [No Abstract] [Full Text] [Related]
19. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?]. Rukavitsyn OA; Pop VP Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606 [No Abstract] [Full Text] [Related]
20. A phenomenal response to treatment by an advanced tumour. Rahman SH; Roy A; Leahy M; Guillou PJ; Toogood GJ Gut; 2004 Nov; 53(11):1582, 1616. PubMed ID: 15479675 [No Abstract] [Full Text] [Related] [Next] [New Search]